The aim of this study was to assess progress in the field of anesthetic drugs over the past 30 years using scientometric indices: popularity indices (general and specific), representing the proportion of articles on a drug relative to all articles in the field of anesthetics (general index) or the subfield of a specific class of anesthetics (specific index); index of change, representing the degree of growth in publications on a topic from one period to the next; index of expectations, representing the ratio of the number of articles on a topic in the top 20 journals relative to the number of articles in all (.5,000) biomedical journals covered by PubMed; and index of ultimate success, representing a publication outcome when a new drug takes the place of a common drug previously used for the same purpose. Publications on 58 topics were assessed during six 5-year periods from 1984 to 2013. Our analysis showed that during 2009-2013, out of seven anesthetics with a high general popularity index ($2.0), only two were introduced after 1980, ie, the inhaled anesthetic sevoflurane and the local anesthetic ropivacaine; however, only sevoflurane had a high index of expectations (12.1). Among anesthetic adjuncts, in 2009-2013, only one agent, sugammadex, had both an extremely high index of change (.100) and a high index of expectations (25.0), reflecting the novelty of its mechanism of action. The index of ultimate success was positive with three anesthetics, ie, lidocaine, isoflurane, and propofol, all of which were introduced much longer than 30 years ago. For the past 30 years, there were no new anesthetics that have produced changes in scientometric indices indicating real progress.
Introduction
Scientometrics is devoted to the measurement of scientific output (publications) as well as of the impact of scientific findings on subsequent developments in related areas of research. This study evaluated the evolution of different anesthetics and techniques of their administration over the past 4 decades using a number of new scientometric indices.
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Vlassakov and Kissin anesthetics have therapeutic indices (median lethal dose/ median effec tive dose [LD 50 /ED 50 ]) that range from 2 to 4, making these among the most dangerous drugs in clinical use". 13 For example, the experimentally determined (in rats) therapeutic index (LD 50 /ED 50 ) of halothane for motor responses is 4.1.
14 Over the past 4 decades, many changes in drugs used for anesthesia may have contributed to the dramatic decrease in mortality and morbidity.
Scientometric assessments of various classes of drugs have been reported in a number of publications. [1] [2] [3] [4] [5] [6] Some of the scientometric indices can be used to indicate certain changes in drug administration. 3, 5, 6 The main aim of this study was to find signs of progress in the use of anesthetics over the period 1984-2013.
Methods
The following scientometric parameters [4] [5] [6] were used as signs of progress in assessment of anesthetics.
general popularity index
The general popularity index (GPI) is the percentage of articles on a specific anesthetic among all articles on anesthetics (Anesthetics [MeSH term]) published over the same 5-year period. A specific threshold of 0.1% for 2009-2013 (arbitrary) was used to select topics for which the number of publications reached a notable level.
Specific popularity index
The specific popularity index (SPI) is the number of articles on a specific anesthetic used to provide one of the following types of anesthesia: inhalational anesthesia (Anesthesia, 
index of change
The index of change (IC) is the percentage change in the number of publications on a drug or technique during a 5-year (or 10-year) period compared with the previous similar period. It reflects the change in general interest in a topic. The specific threshold used for this index was $50, ie, the growth beyond the increase (percent) in number of publications in the whole field of PubMed drug-related articles (Drug [MeSH term]) during the same time interval.
index of expectations
The index of expectations (IE),or Top Journal Selectivity Index, is the ratio of the number of all types of articles on a particular topic in the top 20 journals relative to the number of articles in all (.5,000) biomedical journals covered byindex of ultimate success Index of ultimate success (IUS) is a publication outcome indicating that a new drug (or group of drugs) has taken the place of a drug that had previously been commonly used for the same purpose. It is measured by the degree of decline in SPI of an old, supplanted drug. Decline in the SPI of a supplanted drug $50% during an interval of 10-20 years was selected to represent a positive IUS for the new drug.
The articles were counted using the National Library of Medicine's PubMed website (http://www.ncbi.nlm.nih.gov/ pubmed/) which covers over 21 million journal articles in biomedicine. Various individual anesthetic drug names or terms related to the techniques of their administration were entered in the search box. Filter for languages (English) was used. All types of articles were considered.
The criterion for selection of a particular drug for analysis was the level of its GPI in [2009] [2010] [2011] [2012] [2013] . If the GPI was $0.1, the drug was also assessed using SPI. The IC and IE were determined if the following two criteria were satisfied: the last of the initial 100 articles on a topic was published after 1980 and the number of articles in 2009-2013 was $50. IUS was calculated when a new drug caused a stable decline over 10-15 years in SPI of an alternative drug. The following categories of terms were included in the searches: anesthetics (inhaled, intravenous, and local); anesthetic adjuncts (all drugs that are used to modify the main effects of anesthetics, including analgesics, sedatives, neuromuscular blocking agents with antagonists, and alpha 2-selective adrenergic receptor agonists); and techniques used for anesthetic administration (methods of measuring the main anesthetic effect, ie, depth of sedation, are also included in this category).
The terms were selected from various sources. [15] [16] [17] [18] [19] [20] The following terms were searched: "alfentanil", "atracurium", "benzocaine", "bispectral index", "bupivacaine", "buprenorphine", "chloroprocaine", "cisatracurium", "clonidine", "closed-loop anesthesia", "combined spinal-epidural", "continuous epidural", "continuous nerve block", "continuous spinal", "desflurane", "dexamethasone", "dexmedetomidine", "diazepam", "edrophonium", "enflurane", "entropy", "etomidate", "fentanyl", "gantacurium", "halothane", "isoflurane", "ketamine", "levobupivacaine", "lidocaine", "median electroencephalographic frequency", "mepivacaine", "methohexital", "midazolam", "mivacurium", "morphine", "neostigmine", "nitrous oxide", "pancuronium", " prilocaine", "procaine", "propofol", "pyridostigmine", "remifentanil", "robotic anesthesia", "rocuronium", "ropivacaine", "sevoflurane", "spectral edge frequency", "succinylcholine", "sufentanil", "sugammadex", "target-controlled anesthesia", "tetracaine", "thiopental", "total intravenous anesthesia", "ultrasound-guided block", "vecuronium", "volatile induction", "wound infiltration", and "xenon". Table 1 indicates that, in 2009-2013, 19 anesthetics had a GPI $0.1, comprising six inhaled, four intravenous, and nine local anesthetics. Of the four that were introduced after 1980, two are inhaled anesthetics (sevoflurane and desflurane) and the other two are local anesthetics (ropivacaine and levobupivacaine). Of the 19 anesthetics with a GPI $0.1, seven were higher than 2.0, comprising isoflurane, nitrous oxide, and sevoflurane (among inhaled anesthetics), propofol (among intravenous anesthetics), and lidocaine, bupivacaine, and ropivacaine (among local anesthetics). The SPI indices are presented in Table 1 (right side) and in Figures 1-3 . They indicate that changes in the popularity of anesthetics are usually very slow, with some having high SPIs for a very long time. For example, for the past 40-50 years, the SPI of lidocaine was amazingly stable at 22 in both 1964-1968 and 1999-2003 , then there was a slight decline to 18 (2009-2013) . Nitrous oxide was also highly popular for a long time; however, its popularity has decreased over the past 10 years.
Results anesthetics
As indicated by Table 2 , only five anesthetics met our criteria to measure IE and IC, ie, three general anesthetics (propofol, sevoflurane, and desflurane) and two local anesthetics (ropivacaine and levobupivacaine). In 2009-2013, only sevoflurane and desflurane had an IE higher than the specific threshold of 10, indicating the persistence of high expectations for these agents. At the same time, in 2009-2013, the IC of all five of these drugs was rather low, probably indicating that interest in them has peaked. Table 3 presents the IUS for various anesthetic drugs; lidocaine, isoflurane (combined with sevoflurane), and propofol all reached 50% 10-20 years after their introduction.
anesthetic adjuncts
Anesthetic adjuncts are presented in Table 4 . In 2009-2013, only three drugs demonstrated both impressive increases in interest (IC .50) and high expectations (IE .10), ie, rocuronium, sugammadex (an agent for reversal of rocuroniuminduced neuromuscular block), and dexamethasone (when used as an adjunct to local anesthetics). However, only sugammadex had a very high IE (25.0). Table 5 shows that among the techniques used for anesthetic administration during 2009-2013, there was a high IE (.10) for target-controlled anesthesia (14.6), bispectral index (14.6), and entropy (20.8), the latter two being processed electroencephalogram techniques for monitoring depth of anesthesia. However, in 2009-2013, the IC for these terms did not reach the specific threshold level of 50. Ultrasound-guided block had very high levels of IC over all recent 5-year periods, indicating a dramatic increase in the use of the technique. At the same time, the IE for this technique was above the specific threshold level of 10 in 
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Vlassakov and Kissin rate of publication growth
The rates of 5-year publication growth for each of three classes of anesthetics (inhaled, intravenous, and local) are presented in Figure 4 . In general, the most significant growth was with local anesthetics and the least significant was with inhaled anesthetics. In addition, the most obvious periods of growth for all classes of anesthetics were 1984-1988 and 1989-1993 ; however, for the past 20 years, growth was almost absent. This phenomenon is especially evident in Figure 5 , which compares 10-year growth of publications on anesthetic-related articles with that of all PubMed drugrelated articles (entire pharmacology) and that of all articles related to anesthesia monitoring. In 2004-2013, only growth in articles on anesthesia monitoring was comparable with that of publications on all drugs in general.
Discussion
This is the first study that used specific scientometric indices to determine the evolution in use of anesthetics and to assess signs of progress in the field of anesthesia. It demonstrated that scientometric indices, suggested before [1] [2] [3] [4] [5] [6] and used in this study, can determine evolution of drugs through their presence in articles published in the academic journals. The results presented here indicate that over the past 30 years there were no new anesthetics that produced changes in scientometric indices indicating real progress. The dramatic decrease in anesthesia-related mortality is probably due not so much to the increased safety margins of new anesthetics, but to the improvements in safety rules related to their administration (eg, new anesthesia monitoring techniques and better anesthesiologists training). (Table 1) . Both drugs were developed based on experimental findings that systemic toxicity (mostly cardiotoxicity) of racemic bupivacaine was more pronounced with the R-enantiomer. As a result, the S-enantiomer preparations of ropivacaine and levobupivacaine were introduced to provide long-acting agents with greater safety margins. The following drugs, which did not satisfy at least one of these criteria, were excluded: alfentanil, buprenorphine, cisatracurium, diazapam, edrophonium, gantacurium, mivacurium, morphine, neostigmine, pancuronium, pryridostigmine, and succinylcholine. Despite the lack of good clinical evidence, but with the reliable results of experimental studies, the conclusion was made that ropivacaine is less cardiotoxic than other long-acting local anesthetics. 21, 22 Conclusions on the systemic toxicity of levobupivacaine seem to be less certain.
As far as general anesthetics are concerned, there were no dramatic increases in either IC or IE in 2009-2013; instead, only a steady decline of the very high indices following their introduction. The best example is desflurane, which was introduced in 1990. Its IC was very high in 1994-1998 but then plummeted to almost zero for the next 15 years ( Table 2 ). The SPI of desflurane (Table 1) began to increase in 1994-1998, but remained static over the following 15-year period. This reflected a steep rise in the popularity of sevoflurane. The SPI of general anesthetics revealed the outcomes for another index that requires a long time to develop, ie, the IUS. As stated above, the most important outcome of the introduction of a new drug is the decline in the number of articles about another drug that previously dominated use for the same purpose.
6 Figure 1 and Table 3 illustrate that isoflurane (in combination with sevoflurane) displaced halothane in medicobiological journals over the period of 30 years. Among the intravenous anesthetics, propofol had similar success (Figure 2 and Table 3 ), almost completely displacing thiopental. Among local anesthetics, lidocaine successfully supplanted procaine ( Figure 3 and Table 3 ). As a result, it was not until 10-20 years after their introduction that the IUS of these anesthetics reached the level of 50. After all, these agents were introduced long ago (lidocaine in 1947, isoflurane in 1971, and propofol in 1977).
anesthetic adjuncts
Among the anesthetic adjuncts, only three drugs demonstrated increases above the specific threshold levels for both IC and IE, ie, rocuronium and sugammadex among general anesthetics, and dexamethasone with local anesthetics (Table 3) . Rocuronium is a nondepolarizing neuromuscular blocking agent used to relax skeletal muscles without increasing the depth of anesthesia. Although it was introduced fairly long ago (in 1994), the increased interest in this drug seen in 2009-2013 is probably associated with successful development of sugammadex, an agent for the reversal of neuromuscular blockade induced by rocuronium (or other steroidal nondepolarizing agents) via a novel mechanism of action. 
Margins of safety
Margins of safety are very low with all classes of anesthetics, and major efforts to improve the safety margins of these agents have yielded sparse results. As indicated in the introduction, inhaled anesthetics have very low therapeutic indices, making them "among the most dangerous drugs in clinical use". 13 This was the main reason for the high mortality and morbidity of general anesthesia. Substituting isoflurane and sevoflurane for halothane (Figure 1 ) likely improved the safety of anesthesia; for example, concerns regarding hepatic injury with inhalational anesthesia seem to have disappeared. Notably, the experimentally determined therapeutic index of isoflurane is better than that of halothane. In rats the LD 50 /ED 50 index for motor responses with isoflurane is 1.7 times higher than with halothane.
14 However, the margins of safety of inhaled anesthetics are still too low.
Therapeutic indices (LD 50 /ED 50 ) for intravenous anesthetics in general are not much better than those for inhaled anesthetics. However, the therapeutic index of intravenous anesthetics varies much more than that of inhaled anesthetics. For example, the LD 50 /ED 50 index for motor responses in rats is 3.1 times higher with etomidate than with thiopental. 25 The greater margin of safety in combination with good hemodynamic stability led to the initial widespread use of etomidate, especially in critically ill patients. However, one specific side effect, adrenocortical suppression, has tempered the enthusiasm of anesthesiologists for etomidate. Efforts are currently directed toward creation of an etomidate analog that offers the beneficial properties of this drug without significant adrenocortical suppression. 26 Local anesthetics, if used in large doses to produce epidural anesthesia or blockade of peripheral nerves, also pose the problem of low margins of safety, but to a lesser degree than general anesthetics. Similarly, reported mortality seems to be lower with regional anesthesia than with general anesthesia, according to some studies by about a third. 27, 28 Insufficient progress in finding new anesthetics with appreciably better margins of safety has led anesthesiologists to redouble their efforts to compensate for this drawback. This work has developed along two basic directions, ie, better training of anesthesia providers and improvements in the technology of anesthesia monitoring. The first direction produced the present situation: a physician with 3 years of anesthesia residency training, or a closely supervised nurse anesthetist, usually gives minute-by-minute undivided attention to the status of each anesthetized patient. The other direction has produced various techniques for patient monitoring, such as oximetry, capnography, quantitative neuromuscular blockade monitoring, and processed electroencephalography monitoring, many of which have become standard worldwide. As a result of improved vigilance ("vigilance" has been the motto of the American Society of Anesthesiologists), anesthesiology reached an exceptional position among the branches of medicine and became a model for patient safety. 29 Therefore it is possible that the decrease in anesthesia-related mortality over the past 30-40 years (approximately 10-fold lower compared with 1954-1975) was not produced by the development of anesthetics with better margins of safety, but mostly by improved vigilance while using anesthetics with low margins of safety.
The scientometric indices used to identify signs of progress in the therapeutics (GPI, SPI, IC, IE, and IUS) are Drug Design, Development and Therapy
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